ARTV

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT.

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website.

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London. The five accepted abstracts will be delivered as one late-breaking oral presentation, one oral presentation, one poster view, one poster tour and one publication only.

Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development.

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the pricing of an underwritten offering of 23,871,526 shares of its common stock at a price of $11.52 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 2,170,138 shares of common stock at a purchase price of $11.5199 per share, which equals the offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. All the shares of common stock and pre-funded warrants in the offering are being sold by Artiva.

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026 Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjögren disease (SjD) and systemic sclerosis (SSc) SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent progress. “Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a single Phase 3 registrational trial design in refractory RA,” said Fred Aslan, M.D.

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website.